Figure 3.

Systemic Administration of 16E7 gRNAs and WT Cas9 Packaged in Stealth Liposomes Effectively Clears Established Tumors via Apoptosis

(A) CasKi cells were subcutaneously inoculated in Rag1 mice and allowed to establish (20 mm³), before mice were injected via the tail vein (a total of 10 μg/dose of plasmid DNA expressing 16E7 or control gRNAs + WT Cas9, packaged in stealth liposomes). Tumor volume was monitored over a 3-month period. The arrows represent the days of treatment. (B) Immunohistochemical staining of tumor tissues with H&E or anti-cleaved caspase-3 antibody. (C) The survival analysis of established CasKi xenografts in Rag1 mice after 16E7 targeted treatment, control (nonspecific gRNA + WT Cas9), or untreated (PBS only) in days (D) The apoptotic cell count in anti-caspase-3-stained tumor tissues. Data are presented as mean ± SD. Statistical significance was assessed by ANOVA with post hoc analysis. *p < 0.05, **p < 0.01, ***p < 0.001.